GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (STU:THR) » Definitions » Cyclically Adjusted PS Ratio

ThermoGenesis Holdings (STU:THR) Cyclically Adjusted PS Ratio : 0.00 (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is ThermoGenesis Holdings Cyclically Adjusted PS Ratio?

As of today (2024-05-24), ThermoGenesis Holdings's current share price is €0.482. ThermoGenesis Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €990.87. ThermoGenesis Holdings's Cyclically Adjusted PS Ratio for today is 0.00.

The historical rank and industry rank for ThermoGenesis Holdings's Cyclically Adjusted PS Ratio or its related term are showing as below:

During the past years, ThermoGenesis Holdings's highest Cyclically Adjusted PS Ratio was 2.25. The lowest was 0.01. And the median was 0.15.

STU:THR's Cyclically Adjusted PS Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.17
* Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ThermoGenesis Holdings's adjusted revenue per share data for the three months ended in Mar. 2024 was €0.625. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €990.87 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


ThermoGenesis Holdings Cyclically Adjusted PS Ratio Historical Data

The historical data trend for ThermoGenesis Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings Cyclically Adjusted PS Ratio Chart

ThermoGenesis Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.02 0.01 - -

ThermoGenesis Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ThermoGenesis Holdings's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, ThermoGenesis Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ThermoGenesis Holdings's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ThermoGenesis Holdings's Cyclically Adjusted PS Ratio falls into.



ThermoGenesis Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

ThermoGenesis Holdings's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=0.482/990.87
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ThermoGenesis Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, ThermoGenesis Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.625/131.7762*131.7762
=0.625

Current CPI (Mar. 2024) = 131.7762.

ThermoGenesis Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 706.000 100.560 925.164
201409 709.000 100.428 930.313
201412 941.250 99.070 1,251.991
201503 933.750 99.621 1,235.140
201506 824.500 100.684 1,079.115
201509 503.000 100.392 660.249
201512 604.800 99.792 798.640
201603 423.833 100.470 555.896
201606 378.857 101.688 490.956
201609 258.154 101.861 333.970
201612 172.591 101.863 223.275
201703 138.227 102.862 177.082
201706 141.636 103.349 180.594
201709 117.045 104.136 148.112
201712 113.091 104.011 143.280
201803 63.083 105.290 78.952
201806 50.441 106.317 62.520
201809 54.449 106.507 67.367
201812 42.964 105.998 53.413
201903 47.655 107.251 58.553
201906 61.452 108.070 74.932
201909 56.692 108.329 68.962
201912 22.143 108.420 26.913
202003 31.478 108.902 38.090
202006 14.221 108.767 17.229
202009 13.416 109.815 16.099
202012 9.091 109.897 10.901
202103 5.016 111.754 5.915
202106 6.894 114.631 7.925
202109 10.128 115.734 11.532
202112 8.075 117.630 9.046
202203 8.396 121.301 9.121
202206 9.582 125.017 10.100
202209 3.073 125.227 3.234
202212 2.436 125.222 2.564
202303 1.922 127.348 1.989
202306 0.845 128.729 0.865
202309 0.821 129.860 0.833
202312 0.610 129.419 0.621
202403 0.625 131.776 0.625

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ThermoGenesis Holdings  (STU:THR) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


ThermoGenesis Holdings Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ThermoGenesis Holdings (STU:THR) Business Description

Traded in Other Exchanges
Address
2711 Citrus Road, Rancho Cordova, CA, USA, 95742
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.